Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia

被引:39
作者
Andreani, Marco [1 ]
Testi, Manuela [1 ]
Battarra, Mariarosa [1 ]
Indigeno, Paola [1 ]
Guagnano, Annalisa [1 ]
Polchi, Paola [1 ]
Federici, Giorgio [2 ]
Lucarelli, Guido [1 ]
机构
[1] Fdn IME, Lab Immunogenet & Biol Trapianti, Policlin Tor Vergata, I-00133 Rome, Italy
[2] Policlin Tor Vergata, Dipartimento Med Lab, Rome, Italy
关键词
bone marrow transplantation; mixed chimerism; rejection; thalassaemia;
D O I
10.2450/2008.0051-07
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Thalassaemia is a genetic disease that requires a hypertransfusion regimen to treat the anaemia caused by enhanced red blood cell destruction. The only radical cure for thalassaemia is to correct the genetic defect by bone marrow transplantation from an HLA-identical donor capable of producing and maintaining a normal haemoglobin level in the recipient. Complete donor haematopoiesis is not essential for sustained engraftment and the simultaneous presence of haematopoietic cells of both donor and recipient origin is not a rare event after a transplant. Patients and methods. The evolution of marrow engraftment of 93 transplanted thalassaemic patients, all from Middle East or Asian countries, was monitored by analysis of short tandem repeats. Results. Forty-three of 93(46%) patients experienced a status of mixed chimerism early after bone marrow transplantation. Results of further engraftment analysis in these patients showed in 27 complete donor engraftment; rejection occurred in seven, while eight maintained the presence of both host and donor-derived cells. Interestingly, live out of the seven patients who rejected their transplant showed more than 25% residual host cells early after transplantation. Discussion and conclusion. Our study confirmed that the presence of large amounts of residual host cells within the first 2 months after a transplant is a risk factor for graft rejection also in a group of patients with wide ethnic heterogeneity, irregular transfusion regimens and/or poor chelation treatment. Ten pet-cent of the transplanted thalassaemic patients maintained coexistence of donor and recipient cells, showing a stable functional graft, characterized by normal production of beta globin chains and high levels of haemoglobin. A mechanism responsible for peripheral tolerance induction, such as the production of specific regulatory T-cell clones, seems to play a key role in the induction of long-term tolerance after the transplant.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 17 条
[1]   Long-term survive of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation [J].
Andreani, M ;
Nesci, S ;
Lucarelli, G ;
Tonucci, P ;
Rapa, S ;
Angelucci, E ;
Persini, B ;
Agostinelli, F ;
Donati, M ;
Manna, M .
BONE MARROW TRANSPLANTATION, 2000, 25 (04) :401-404
[2]   Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia [J].
Andreani, M ;
Manna, M ;
Lucarelli, G ;
Tonucci, P ;
Agostinelli, F ;
Ripalti, M ;
Rapa, S ;
Talevi, N ;
Galimberti, M ;
Nesci, S .
BLOOD, 1996, 87 (08) :3494-3499
[3]   HIGH-LEVELS OF INTERLEUKIN-10 PRODUCTION IN-VIVO ARE ASSOCIATED WITH TOLERANCE IN SCID PATIENTS TRANSPLANTED WITH HLA MISMATCHED HEMATOPOIETIC STEM-CELLS [J].
BACCHETTA, R ;
BIGLER, M ;
TOURAINE, JL ;
PARKMAN, R ;
TOVO, PA ;
ABRAMS, J ;
MALEFYT, RD ;
DEVRIES, JE ;
RONCAROLO, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :493-502
[4]   Mixed chimerism and transplantation tolerance [J].
Cosimi, AB ;
Sachs, DH .
TRANSPLANTATION, 2004, 77 (06) :943-946
[5]   Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model [J].
Huang, CA ;
Fuchimoto, Y ;
Scheier-Dolberg, R ;
Murphy, MC ;
Neville, DM ;
Sachs, DH .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (02) :173-181
[6]   ANALYSIS OF BETA-GLOBIN MUTATIONS SHOWS STABLE MIXED CHIMERISM IN PATIENTS WITH THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION [J].
KAPELUSHNIK, J ;
OR, R ;
FILON, D ;
NAGLER, A ;
CIVIDALLI, G ;
AKER, M ;
NAPARSTEK, E ;
SLAVIN, S ;
OPPENHEIM, A .
BLOOD, 1995, 86 (08) :3241-3246
[7]   MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
ANDREANI, M ;
AGOSTINELLI, F ;
ALBERTINI, F ;
CLIFT, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (12) :840-844
[8]   The cure of thalassemia by bone marrow transplantation [J].
Lucarelli, G ;
Andreani, M ;
Angelucci, E .
BLOOD REVIEWS, 2002, 16 (02) :81-85
[9]   Advances in the allogeneic transplantation for thalassemia [J].
Lucarelli, Guido ;
Gaziev, Javid .
BLOOD REVIEWS, 2008, 22 (02) :53-63
[10]  
MANNA M, 1993, BONE MARROW TRANSPL, V12, P70